Under some conditions, mononuclear phagocytes spontaneously synthesize and release fibronectin, an extracellular matrix glycoprotein with versatile effects on cell-matrix interactions. To gain insight into the processes that modulate the level of fibronectin secretion by these cells, we used monocytes, in vitro matured monocytes and alveolar macrophages as models to compare fibronectin mRNA levels and fibronectin secretion in a variety of circumstances. Using Northern analysis and dot-blot analysis with a 32P-labeled human fibronectin cDNA probe, we evaluated steady-state mRNA levels and a human fibronectin-specific ELISA was used to evaluate fibronectin secretion. In all cases the amounts of fibronectin secreted paralleled fibronectin mRNA levels. Specifically (a) when fibronectin mRNA was undetectable, as in the case of normal blood monocytes, no fibronectin was secreted, but whenever fibronectin mRNA was present, as in normal alveolar macrophages, fibronectin was secreted by the cells; (b) as monocytes matured into macrophages in vitro, the cells began to express fibronectin mRNA and the cells secreted fibronectin; (c) when alveolar macrophages were activated with surface stimuli such as lipopolysaccharide (LPS) or immune complexes, fibronectin mRNA levels decreased and in parallel, the cells secreted less fibronectin; (d) in idiopathic pulmonary fibrosis (IPF), alveolar macrophages contained severalfold more fibronectin mRNA transcripts that normal and the cells spontaneously secreted severalfold more fibronectin than normal; and (e) when IPF alveolar macrophages were placed […] 
Introduction
Fibronectin is a 440,000-D dimeric glycoprotein produced by a variety of cells and capable of functioning in a broad range of biologic processes including cell adhesion, spreading, cytoskeletal organization, migration, proliferation, and differentiation (1) (2) (3) (4) (5) . Fibronectin accomplishes these diverse processes by acting as a ligand between cells and macromolecules through the use of structural domains in the fibronectin molecule with affinity for collagen, heparin, fibrin, DNA, and cell surfaces (1) (2) (3) (4) (5) .
One source of fibronectin is the alveolar macrophage, a bone marrow-derived mononuclear phagocyte that plays a major role in inflammatory processes in the lower respiratory tract in health and disease (6) (7) (8) . Several studies have demonstrated that alveolar macrophages synthesize and secrete fibronectin and that alveolar macrophages associated with chronic inflammatory diseases of the lower respiratory tract secrete exaggerated amounts of this molecule (6) (7) (8) . In the context of the known functions of fibronectin, it is likely that it represents one of the alveolar macrophage mediators that plays a role in both defending the lung and in modulating the damage and repair that accompanies inflammatory processes in the lower respiratory tract (6) (7) (8) (9) (10) (11) (12) (13) (14) .
With this background, the present study was designed to evaluate the level at which production of fibronectin by human mononuclear phagocytes is modulated. To accomplish this, we have quantified fibronectin mRNA levels and fibronectin secretion in these cells under a variety of conditions, including circumstances where fibronectin secretion appears to be undetectable, up-regulated, and down-regulated. The data obtained are consistent with the concept that, in many situations, fibronectin secretion by these cells is regulated by steady-state fibronectin mRNA levels.
Methods
Study population. The normal population consisted of 10 nonsmoking individuals (seven males, three females; mean age, 33±2 yr [all data are presented as mean±SE; all statistical comparisons are made using the two-tailed Student's t test]) with no history of lung disease. All had normal lung function tests and chest x rays. None were taking medications. The "fibrotic" lung disorder, idiopathic pulmonary fibrosis (IPF),' was used as an example of a chronic inflammatory lung disorder in which it is known that alveolar macrophages are producing elevated levels of fibronectin (7) . This population consisted of 19 individuals (1 1 males, 8 females; mean age, 54±3 yr) in whom the diagnosis of IPF was made using established criteria, including open lung biopsy (15) . All patients were in mid-course oftheir disease (16) . Ofthe 19, 1 1 were taking no medications and 8 were taking prednisone at the time of evaluation. Nine were lifelong nonsmokers and 10 had a history of cigarette smoking but had discontinued smoking at least 3 yr before evaluation. As a group, the patients with IPF had the following functional abnormalities (15) MD). After baking (2 h, 800) the nitrocellulose filter paper was hybridized using the 32P-labeled fibronectin cDNA probe. Fibronectin mRNA from fetal lung fibroblasts (HFL-1; ATCC CCL1 53) was used as a standard. Arbitrarily, 2.5 ,g oftotal fibroblast RNA was defined as containing 1 U fibronectin mRNA. As a control for studies evaluating fibronectin mRNA levels following activation of normal alveolar macrophages, interleukin-1 mRNA levels were quantified using a human interleukin-1 P cDNA probe (26). As a control for studies evaluating the time-dependent changes in fibronectin mRNA levels during in vitro culture of IPF alveolar macrophages, apolipoprotein E mRNA levels were quantified using an apolipoprotein E cDNA probe (kindly provided by S. W. Law and H. B. Brewer, Molecular Disease Branch, National Heart, Lung and Blood Institute) (27) . All probes were labeled by nick translation using [32P]dCTP (3, Second, these parameters were quantified during the maturation of monocytes to macrophages in culture. To accomplish this, monocytes were cultured from 1 to 14 d (4 X 107 monocytes/plate; 10 cm diameter petri dish) in DME, 10% heat-inactivated fetal bovine serum (Gibco, Grand Island, NY), and 50 ,g/ml gentamycin. The medium was changed every 3 d. Fibronectin mRNA levels were determined at various time points and in parallel cultures the secretion of fibronectin was evaluated by removing the old culture media and culturing cells in fresh serum-free medium over a 24-h period.
Third, based on the knowledge that alveolar macrophages from patients with IPF secrete severalfold higher amounts of fibronectin than normal alveolar macrophages (7), fibronectin mRNA levels and secretion were compared in alveolar macrophages from normals and patients with IPF. The mRNA levels were evaluated in the cells immediately after lavage. For evaluation of fibronectin secretion, the cells recovered by lavage were cultured in DME (1 X 107 macrophages/ plate) without serum for 1 h, 37°. The nonadherent cells were removed by vigorous washing, fresh medium was added, the cells were incubated for 24 h, and the supernatants were collected.
Fourth, normal alveolar macrophages were evaluated after activation. Alveolar macrophages from normal individuals were divided into three groups: cultured in serum-free DME alone, with the addition of lipopolysaccharide (LPS, Escherichia coli 0127; B8, Difco Laboratories Inc., Detroit, MI; 10 Mg/ml), or immune complexes (human albumin and rabbit anti-human albumin, Cappel Laboratories, Cochran- ville, PA; final protein concentration of 10 ,g/ml) (30) . All 2 and 4) . The sizes of the fibronectin and -y-actin mRNA transcripts were determined using DNA markers (see Methods). (B) Secretion of fibronectin by normal monocytes and alveolar macrophages. The cells were cultured in DME without serum for 24 h and the supernatants evaluated for the presence of fibronectin by ELISA. *Undetectable.
were evaluated for fibronectin levels every 4 h for up to 12 h and then over the subsequent 12 h.
Results
Spontaneous fibronectin gene expression by normal blood monocytes and alveolar macrophages. There was a marked difference in fibronectin mRNA levels in normal blood monocytes and normal alveolar macrophages (Fig. 1 A) . In all cases, Northern analysis of RNA extracted from normal monocytes and alveolar macrophages demonstrated that blood monocytes did not contain any fibronectin mRNA, whereas alveolar macrophages spontaneously expressed a 7.8-kb fibronectin specific mRNA. In contrast to the difference in fibronectin mRNA levels between the two cell types, evaluation of the same RNA samples demonstrated that the y-actin gene was expressed by both blood monocytes and alveolar macrophages. This difference in fibronectin mRNA levels was paralleled by a difference in fibronectin secretion by these cells.
Whereas normal blood monocytes did not release any detectable amount of fibronectin, normal alveolar macrophages spontaneously released large amounts of fibronectin (Fig. 1 B) . Fibronectin gene expression during monocyte maturation. Because alveolar macrophages, a differentiated form of monocytes, spontaneously expressed the fibronectin gene whereas blood monocytes did not, it is reasonable to hypothesize that the maturation process is accompanied by the spontaneous expression of this gene. To evaluate this hypothesis, blood monocytes were cultured in vitro and allowed to mature over a period of 14 d, and expression of the fibronectin gene was evaluated. Consistent with the hypothesis, as monocytes matured in vitro, they began to demonstrate fibronectin mRNA transcripts and these levels increased with time (Fig. 2 A) . In this experiment, the RNA/cell ratio increased during in vitro by Northern analysis demonstrated they were 7.8 kb, similar to those of normal alveolar macrophages (not shown). Furthermore, the increasing levels of fibronectin mRNA were paralleled by the amounts secreted per 24 h increasing with time in culture (Fig. 2 B) (Fig. 3 A) . However, Northern analysis demonstrated that the form of the fibronectin mRNA was similar to that found in fresh cells, i.e., 7.8 kb (not shown). This was not a result ofa general down-regulation of gene expression. Both stimuli caused the alveolar macrophages to increase interleukin-1I3 gene expression (Fig. 3 B) and of interleukin-1 release (data not shown). Furthermore, the apparent down-regulation of fibronectin mRNA levels was paralleled by a decrease in the spontaneous release of fibronectin (LPS, 60±3% of control; immune complexes, 57±5% of control; P < 0.01, both comparisons, Fig. 3 C) , i.e., the addition of LPS or immune complexes reduced fibronectin mRNA levels and fibronectin secreted by the normal alveolar macrophages (Fig. 3 , A and C). In marked contrast, both stimuli caused the alveolar macrophages to increase interleukin-1I gene expression (Fig. 3 B) and of interleukin-1 release (data not shown).
Exaggerated fibronectin gene expression by alveolar macrophagesfrom patients with IPF. Quantification of fibronectin mRNA levels by dot-blot analysis demonstrated that the level of fibronectin mRNA in alveolar macrophages from patients with IPF was eightfold higher than in normals (Fig. 4 A; P < 0.01). Northern analysis showed that the size of fibronectin mRNA in the IPF alveolar macrophages was similar to that in normal alveolar macrophages (not shown). No differences were observed in fibronectin mRNA levels among ex-smokers and among individuals not treated or those treated. In parallel with this observation, as previously shown, alveolar macrophages from patients with IPF spontaneously secreted more fibronectin than normal alveolar macrophages (7) . In this regard, alveolar macrophages from patients with IPF secreted eightfold more fibronectin than normals (Fig. 4 B ; P < 0.01), i.e., alveolar macrophages from these individuals appeared to have up-regulated the fibronectin gene.
Time-dependent change ofJibronectin gene expression by alveolar macrophages from patients with IPF maintained in culture. Because alveolar macrophages of IPF patients appear to have up-regulated the fibronectin gene compared with normals, we asked whether this exaggerated fibronectin gene expression was a constitutive property of these cells. To answer this question, alveolar macrophages from patients with IPF were cultured in serum-free DME and fibronectin mRNA levels and fibronectin secretion evaluated over time (Fig. 5 ). This levels of fibronectin mRNA in these alveolar macrophages after 24 h in culture was reduced to one-third of the original level (P < 0.01; Fig. 5 A) . However, Northern analysis showed the size of the fibronectin mRNA transcripts were 7.8 kb, same as normal (not shown). This change was not a non- were quantified using dot-blot analysis as described in Fig. 2 (42) . There is one fibronectin gene per parental genome (43, 44) . Using blood monocytes, in vitro matured macrophages, normal alveolar macrophages, and alveolar macrophages recovered from individuals with the chronic inflammatory lung disease, the present study demonstrates that the amounts of fibronectin secreted could be related to the levels of fibronectin mRNA within the population of cells evaluated. The mechanism of this increase is unknown. Measurement (42, (44) (45) (46) (47) (48) (49) (50) (51) (52) (53) (54) (55) (56) (57) . Whereas such variations appear to relate, at least in part, to cell specificities producing the fibronectin (48, 53) , it is not known if the process of alternative splicing relates in any fashion to modulating fibronectin mRNA levels for a given cell.
Despite the extensive study ofthe structure and function of fibronectin at the protein level and the structure of fibronectin at the gene level, little is known about the levels at which cells modulate the expression ofthis gene. Presumably, the variable levels of fibronectin mRNA observed in the various circumstances evaluated in the present study are modulated at the level of fibronectin gene transcription. For example, Raghow et al. (58) have recently observed that in the lungs of bleomycin-treated hamsters, the rate of nuclear transcription of the fibronectin gene paralleled the temporal changes in steadystate fibronectin mRNA levels. Likewise, the decreased fibronectin mRNA levels observed with transformation of embryo fibroblasts by the Rous sarcoma virus are thought to result from decreased transcription and not changes in fibronectin mRNA stability (59) . However, we have only evaluated steady-state mRNA levels. Furthermore, no information is available at this time regarding the structure and/or function ofthe controlling elements for fibronectin gene expression, nor of the mechanisms modulating the fibronectin mRNA lifespan.
Besides the general observation of the correlation of fibronectin mRNA levels and fibronectin secretion by mononuclear phagocytes, two phenomena observed in the expression of the fibronectin gene by these cells were striking. First, despite the fact that stimuli like LPS and immune complexes up-regulate the production of many mediators by mononuclear phagocytes (60, 61), these stimuli were incapable of stimulating monocytes to express this gene or of stimulating alveolar macrophages to up-regulate the fibronectin gene. Second, alveolar macrophages from individuals with IPF appear to have markedly up-regulated fibronectin genes. However, when placed in culture, this up-regulation was rapidly lost. Because this occurred while the expression of genes coding for other secretory proteins like apolipoprotein E remained constant, this suggests that either the in vivo stimulus had been lost (i.e., and hence the in vitro down-regulation) or that the mechanisms of fibronectin mRNA degradation were up-regulated by the artificial context of in vitro culture. Whatever the actual mechanism, it is clear that fibronectin gene expression in mononuclear phagocytes did not appear to follow the patterns established for many other mononuclear phagocyte mediators.
